1. | EXECUTIVE SUMMARY |
1.1. | Cardiovascular disease (CVD) |
1.2. | CVD: Number 1 killer and heavy economic burden |
1.3. | Report summary |
1.4. | Artificial intelligence (AI) in CVD imaging: Active companies |
1.5. | Drivers & constraints of AI in cardiovascular imaging |
1.6. | AI in cardiovascular imaging: Investments & funding |
1.7. | AI in cardiovascular imaging: Remarks & outlook |
1.8. | The value of point-of-care (POC) testing |
1.9. | Devices for CVD biomarker detection: Key players |
1.10. | LFAs for CVD biomarker detection: Key players |
1.11. | In vitro diagnostics at point-of-care: Remarks and outlook |
1.12. | Electrode-based wearable accessories for RPM |
1.13. | Smart clothing for RPM |
1.14. | Electronic skin patches for RPM |
1.15. | Wearable optical sensing technologies |
1.16. | Blood pressure monitoring technologies |
1.17. | Ambulatory cardiac monitoring: Historic revenues & forecast |
1.18. | Smart clothing suitable for RPM: Historic revenues & forecast |
1.19. | Wearable accessories for RPM: Historic revenue data |
1.20. | Wearable accessories for RPM: Revenue forecast |
1.21. | Wearables for RPM: Remarks & outlook |
1.22. | Non-wearables for RPM: Remarks & outlook |
1.23. | Cardiac rhythm management: Key players & devices |
1.24. | Cardiac devices: Market share |
1.25. | Cardiac devices: Market forecast 2019-2029 |
1.26. | Devices for cardiac rhythm management and heart failure: Remarks & outlook |
1.27. | Heart failure treatment: Moving towards 3D bioprinted cardiovascular tissue |
1.28. | 3D bioprinting cardiovascular tissue: Opportunities |
1.29. | 3D bioprinting cardiovascular tissue: Remarks & outlook |
1.30. | Other treatments: Remarks & outlook |
1.31. | Key conclusions & takeaways |
2. | INTRODUCTION |
2.1. | Scope of report |
2.2. | The heart |
2.3. | Cardiovascular disease (CVD) |
2.4. | Coronary heart disease leads to heart attack |
2.5. | Stroke |
2.6. | Arrhythmia |
2.7. | Atrial fibrillation |
2.8. | Heart failure |
2.9. | Other cardiovascular disorders |
2.10. | Some CVDs are interlinked - one may lead to another |
2.11. | Incidence of CVD |
2.12. | Economic and healthcare costs of CVD |
2.13. | CVD technologies: Market drivers |
2.14. | Report summary |
3. | DETECTION & DIAGNOSIS |
3.1. | Artificial intelligence in cardiovascular imaging |
3.1.1. | Traditional cardiovascular imaging methods |
3.1.2. | Enter artificial intelligence (AI) |
3.1.3. | Drivers & constraints of AI in cardiovascular imaging |
3.1.4. | Innovations in cardiovascular imaging |
3.1.5. | Using imaging & AI to build 3D virtual models |
3.1.6. | Centerline Biomedical: Vasculature models for catheter navigation |
3.1.7. | inHEART: Cardiac models for intervention planning |
3.1.8. | Using imaging & AI to detect clots and blockages |
3.1.9. | iSchemaView: Assessing ischaemic brain injury |
3.1.10. | iSchemaView: Assessing ischaemic brain injury (2) |
3.1.11. | Sensome: Categorising blood clots and tissue composition |
3.1.12. | HeartFlow: Identifying coronary artery blockages |
3.1.13. | Other AI-driven cardiovascular imaging technologies |
3.1.14. | AI to analyse cardiovascular images |
3.1.15. | AI to analyse cardiovascular images (2) |
3.1.16. | HeartVista: Autonomous MRI imaging |
3.1.17. | Further AI uses: Predicting cardiac events |
3.1.18. | Catalia Health: Home healthcare robot assistant |
3.1.19. | Detecting cardiac events through sounds |
3.1.20. | Automation of cardiac electric signal reading |
3.1.21. | AI in cardiovascular imaging: Investments |
3.1.22. | AI in cardiovascular imaging: Funding |
3.1.23. | AI in healthcare: Regulations & path to approval |
3.1.24. | Imaging devices: Regulations & path to approval |
3.1.25. | Radiation from imaging devices: Safety regulations |
3.1.26. | Concluding remarks & outlook |
3.2. | In vitro diagnostics at point-of-care |
3.2.1. | Point-of-care diagnostics can increase standards of care |
3.2.2. | Biosensors, bioreceptors and biotransducers |
3.2.3. | The value of POC testing |
3.2.4. | Biomarkers: indicators of disease |
3.2.5. | Characterizing different POC biosensor technologies |
3.2.6. | cTnI measurement using LOAC devices |
3.2.7. | cTnI measurement via LAOC: iSTAT |
3.2.8. | Stroke detection via LOAC: Evidence MultiSTAT |
3.2.9. | Cholesterol: An indicator of CVD risk & onset |
3.2.10. | Electrochemical test strips: cholesterol detection |
3.2.11. | Cholesterol electrochemical test strips - Key players |
3.2.12. | Other electrochemical test strips for CVD |
3.2.13. | The future of electrochemical test strips |
3.2.14. | Lateral flow assays (LFAs) at point-of-care |
3.2.15. | LFAs for CVD biomarker detection: Key players |
3.2.16. | Commercial cardiac LFA tests |
3.2.17. | Commercial cardiac LFA devices |
3.2.18. | Detection of CVD biomarkers via LFA: Roche |
3.2.19. | LFA: Measuring multiple biomarkers simultaneously |
3.2.20. | Innovations in cTnI LFA testing: MIP Diagnostics |
3.2.21. | Lipid profiling via LFA: Alere |
3.2.22. | Molecular diagnostics (MDx): From the lab to POC |
3.2.23. | Applications of MDx at POC for CVD diagnosis |
3.2.24. | MDx to prevent adverse response to anticoagulant drugs |
3.2.25. | Molecular POC devices still have a long way to go |
3.2.26. | Challenges of developing POC MDx devices for CVD |
3.2.27. | POC devices: Regulatory routes to market |
3.2.28. | POC devices: Regulatory road map in the US |
3.2.29. | Concluding remarks and outlook |
4. | REMOTE PATIENT MONITORING |
4.1. | Wearable technology for remote patient monitoring |
4.1.1. | Cardiovascular monitoring via wearable devices |
4.1.2. | American Well and the rise of RPM |
4.1.3. | Key American Well Partnerships in cardiovascular health |
4.1.4. | Wearable vs implantable monitoring |
4.1.5. | Biotronik: Injectable cardiac monitor |
4.1.6. | Electrode-based wearable cardiac monitors |
4.1.7. | Heart monitoring using electrodes |
4.1.8. | Measuring biopotential |
4.1.9. | The circuitry for measuring biopotential |
4.1.10. | Electrocardiogram (ECG) |
4.1.11. | What do ECG readings mean? |
4.1.12. | Innovations in ECG devices |
4.1.13. | Progress towards ambulatory cardiac monitoring |
4.1.14. | Differentiation between ambulatory cardiac monitors |
4.1.15. | Electrode-based wearable accessories for RPM |
4.1.16. | Smart watch: Apple Watch Series 5 |
4.1.17. | Apple Watch: Clinical studies |
4.1.18. | Smart watch: Withings' Move ECG |
4.1.19. | Chest strap: Custo-Med |
4.1.20. | Necklace: toSense CoVa |
4.1.21. | Smart clothing for RPM |
4.1.22. | Smart clothing: WeHealth |
4.1.23. | Smart clothing: ChronoLife |
4.1.24. | Smart clothing: Hexoskin |
4.1.25. | Smart clothing: Myant |
4.1.26. | Electronic skin patches for RPM |
4.1.27. | Skin patches: VivaLNK |
4.1.28. | Skin patches: Holst Center |
4.1.29. | Skin patches: Cardiomo |
4.1.30. | Other cardiac monitoring skin patches |
4.1.31. | Wearable optical sensors for HRM and more |
4.1.32. | Photoplethysmography (PPG) |
4.1.33. | Transmission-mode PPG vs Reflectance-mode PPG |
4.1.34. | Wearable optical sensing technologies |
4.1.35. | Valencell |
4.1.36. | Philips |
4.1.37. | Well Being Digital (WBD101) |
4.1.38. | APM |
4.1.39. | Sky Labs |
4.1.40. | Monitoring blood pressure and flow |
4.1.41. | What is blood pressure? |
4.1.42. | How is blood pressure measured? |
4.1.43. | History of blood pressure monitoring devices |
4.1.44. | Inferring blood pressure from other heart biometrics |
4.1.45. | Blood pressure monitoring technologies |
4.1.46. | Blood pressure monitoring: Withings |
4.1.47. | Blood pressure monitoring: Omron |
4.1.48. | Blood pressure monitoring: Tarilian Laser Technologies |
4.1.49. | Blood flow monitoring: Ida Health |
4.1.50. | Wearable cardiac monitoring technologies in clinical trials |
4.1.51. | Ambulatory cardiac monitoring: Historic revenue data |
4.1.52. | Ambulatory cardiac monitoring: Revenue forecast |
4.1.53. | Smart clothing suitable for RPM: Historic revenue data |
4.1.54. | Smart clothing suitable for RPM: Revenue forecast |
4.1.55. | Wearable accessories for RPM: Historic revenue data |
4.1.56. | Wearable accessories for RPM: Revenue forecast |
4.1.57. | Wearables for RPM: concluding remarks & outlook |
4.2. | Non-wearable technology for remote patient monitoring |
4.2.1. | Cardiovascular monitoring using non-wearable devices |
4.2.2. | Evolution of the Stethoscope into the Digital Realm |
4.2.3. | Digital stethoscopes |
4.2.4. | Smart scale: Withings |
4.2.5. | Contact-free patient monitoring: EarlySense |
4.2.6. | Portable devices for cardiac monitoring |
4.2.7. | Portable devices: AliveCor |
4.2.8. | Portable devices: BioTelemetry, Inc. |
4.2.9. | Non-wearable technologies in clinical trials |
4.2.10. | Non-wearables for RPM: concluding remarks & outlook |
5. | TREATMENT |
5.1. | Devices for cardiac rhythm management and heart failure |
5.1.1. | Cardiac devices can provide treatment where drugs can't |
5.1.2. | Devices for cardiac rhythm management: Key players |
5.1.3. | Market drivers and Constraints |
5.1.4. | Devices for cardiac rhythm management |
5.1.5. | Cardiac Device Components |
5.1.6. | Implantation Procedure |
5.1.7. | Pacemakers and other cardiac rhythm implants |
5.1.8. | Pacemakers |
5.1.9. | Leadless Pacemakers |
5.1.10. | Medtronic: CareLink |
5.1.11. | Medtronic: CareLink (2) |
5.1.12. | Boston Scientific: Latitude |
5.1.13. | Arrhythmia treatment: Transcatheter ablation |
5.1.14. | Transcatheter ablation techniques and their limitations |
5.1.15. | Transcatheter ablation equipment |
5.1.16. | Transcatheter ablation innovations: DiamondTemp |
5.1.17. | Transcatheter ablation innovations: Helios II system |
5.1.18. | Transcatheter ablation innovations: APAMA RF |
5.1.19. | Heart failure treatment |
5.1.20. | Automated external defibrillators |
5.1.21. | Portable external defibrillators: Zoll |
5.1.22. | Cardiac Resynchronization Therapy |
5.1.23. | Implantable Cardioverter Defibrillators |
5.1.24. | Extravascular Cardioverter Defibrillator |
5.1.25. | Carotid sinus nerve stimulator: CVRx |
5.1.26. | Cardiac Contractility Modulators: Impulse Dynamics |
5.1.27. | Cardiac device development opportunities |
5.1.28. | Ongoing Clinical Trials |
5.1.29. | Regulations: Device invasiveness |
5.1.30. | Regulations: Path to market |
5.1.31. | Cardiac devices: Market share |
5.1.32. | Cardiac devices: Market forecast 2019-2029 |
5.1.33. | Concluding remarks & outlook |
5.2. | Cardiovascular tissue engineering and 3D bioprinting |
5.2.1. | Introduction |
5.2.2. | Drivers & constraints |
5.2.3. | Current options for HF treatment |
5.2.4. | Current options for HF treatment: LVADs |
5.2.5. | Current options for HF treatment: Artificial hearts |
5.2.6. | Moving towards 3D bioprinting: Heart Sheet |
5.2.7. | Methods of cardiovascular tissue engineering |
5.2.8. | Scaffolds for tissue engineering |
5.2.9. | Biodegradable scaffold materials |
5.2.10. | Properties of scaffolds |
5.2.11. | Challenges of cardiac tissue engineering |
5.2.12. | Significant challenge: vascularisation |
5.2.13. | 3D bioprinting |
5.2.14. | 3D Bioprinting Process |
5.2.15. | Manufacturing 3D bioprinted blood vessels |
5.2.16. | Tissue engineering for heart muscle regeneration |
5.2.17. | 3D bioprinted cardiac patches |
5.2.18. | 3D bioprinted blood vessels |
5.2.19. | 3D bioprinting the human heart |
5.2.20. | Opportunities for 3D bioprinting cardiovascular tissue |
5.2.21. | Beyond tissue regeneration |
5.2.22. | Clinical studies |
5.2.23. | Regulatory roadblocks - USA |
5.2.24. | Regulatory roadblocks - EU & UK |
5.2.25. | Concluding remarks & outlook |
5.3. | Other treatments of CVD |
5.3.1. | Options for CVD treatment are numerous |
5.3.2. | Ultrasound to remove calcium deposits |
5.3.3. | Cardiac shockwave therapy |
5.3.4. | SuperSaturated Oxygen (SSO2) |
5.3.5. | 3D printing as a CVD treatment tool |
5.3.6. | 3D printing: Cardiac models for patient-specific care |
5.3.7. | 3D printing: Custom valves and stents |
5.3.8. | 3D printing: Bespoke valves for aortic valve replacement |
5.3.9. | Concluding remarks & outlook |
6. | CONCLUSIONS |
6.1. | Key takeaways |
7. | COMPANY PROFILES |
7.1. | List of company profiles |
7.2. | Life Sciences Research |